Navigation Links
Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest

- Faster delivery, efficient supply chain, and reduced cost for

pharmaceutical manufacturers

NEW YORK, April 14 /PRNewswire/ -- Sumitomo Corporation of America (SCOA) has reached an agreement with Chiral Quest, Inc., a manufacturer and developer of chiral products using proprietary chiral technologies, for the distribution and sale of chiral products to the pharmaceutical industry.

Effective immediately, Sumitomo will be the exclusive sales agent for Chiral Quest in Japan and selected worldwide accounts.

More than 40 percent of the ethical drugs manufactured today utilize chiral intermediate technology. Chiral chemocatalysts play a key role in the manufacture of medicines, fine chemicals, agricultural chemicals, and flavors and fragrances.

"Chiral Quest is now in an expansion phase, and Sumitomo's international network of marketing and distribution facilities will enable us to provide our specialty chiral molecules quickly to pharmaceutical manufacturers globally at competitive prices," said Dr. Joseph Marasco, CEO of Chiral Quest. "This is a venture that will be welcomed by the chiral molecule marketplace, and will allow us to efficiently serve our growing client base."

Chiral Quest has wholly owned patents on a range of innovative chemical catalysts and processes used in the synthesis of chiral molecules. The company's primary laboratory and manufacturing facilities in New Jersey and China will now be supported by Sumitomo's extensive marketing capability and distribution network. Additional information on Chiral Quest is available at their website

"Sumitomo has been a major supplier to the global pharmaceutical industry for over the past four decades," noted Yasunori Ishibashi, senior director of the SCOA Medical Sciences Group. "This collaboration makes it possible for Sumitomo to play a significant role in the innovative and growing field of chiral technology."

Sumitomo's established supply chain provides chemicals for a range of manufacturing processes. The company's chemical experts help specific clients in the field select and implement the most efficient synthesis process for producing specific molecules.

The catalytic asymmetric hydrogenation process was discovered in 1987 by Dr. Ryoji Nyori. Over the past two decades, Nyori chiral technology has evolved rapidly and become widely applied in chemocatalysis. It has been especially valuable in the manufacture of chiral pharmaceutical products and fine chemicals. In 2001 Dr. Nyori shared the Nobel Prize in Chemistry with William S. Knowles for their work in the study of chirally catalyzed hydrogenation.

Sumitomo's global network includes 148 offices in 67 countries. Sumitomo also provides unique expertise in the import and export business.

Through its global network for sales and distribution, Sumitomo has become a major resource for pharmaceutical companies. Sumitomo provides raw materials, production facilities, R&D facilities and various technical process support to major manufacturers in the pharmaceutical industry.

About Sumitomo Corporation of America

Sumitomo Corporation of America (SCOA), is a fully integrated trading and investment enterprise with offices in 11 major U.S. cities. SCOA is the largest wholly owned subsidiary of Sumitomo Corporation (SC), an integrated global trading firm with diversified investments and businesses. Established in 1952, and headquartered in New York, SCOA is involved in a wide range of industries, including working on a global scale with SC and subsidiaries to expand on emerging opportunities in the pharmaceutical industry.

SOURCE Sumitomo Corporation of America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
2. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
3. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
4. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
5. Chem Rx Corporation Reports Full Year 2007 Financial Results
6. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
7. Genaera Corporation Announces 2007 Financial Results
8. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
9. Immunosyn Corporation Announces 2007 Results, Files 10KSB
10. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
11. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):